Mounjaro Japan 5mg | マンジャロ®皮下注5mgアテオス®

Mounjaro® Subcutaneous Injection 5 mg ATEOS® is a prescription medication developed by Eli Lilly Japan K.K. and distributed in collaboration with Mitsubishi Tanabe Pharma Corporation. It is specifically designed for the treatment of type 2 diabetes mellitus in adults.

 

---

 

 

Product Overview

 

 

• Generic Name: Tirzepatide

• Brand Name: Mounjaro® 5 mg ATEOS®

• Formulation: 5 mg/0.5 mL pre-filled single-use autoinjector pen

• Packaging: Typically, two pens per box (providing a two-week supply)

• Administration: Once-weekly subcutaneous injection

• Approval in Japan: September 26, 2022 

 

 

---

 

 

Mechanism of Action

 

Mounjaro® is the world’s first dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. This dual action enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite, leading to improved glycemic control and potential weight loss. 

 

---

 

 

Dosage and Administration

 

 

• Initiation: Start with 2.5 mg once weekly for the first 4 weeks.

• Maintenance: Increase to 5 mg once weekly thereafter.

• Titration: If additional glycemic control is needed, the dose may be increased in 2.5 mg increments every 4 weeks, up to a maximum of 15 mg once weekly. 

 

 

---

 

 

ATEOS® Autoinjector Features

 

The ATEOS® device is a user-friendly, single-use autoinjector designed for ease of administration:

 

• Pre-installed Needle: No need for manual needle handling.

• Automatic Injection: Pressing the injection button inserts the needle and delivers the dose automatically.

• Subcutaneous Delivery: Intended for injection into the abdomen, thigh, or upper arm. 

 

 

---

 

 

Storage Guidelines

 

 

• Refrigeration: Store unused pens in a refrigerator at 2°C to 8°C.

• Room Temperature: Once in use, pens can be stored at room temperature (below 30°C) for up to 21 days.

• Do Not Freeze: Avoid freezing the pens. 

 

 

---

 

 

Indications

 

Mounjaro® is indicated for:

 

• Improving glycemic control in adults with type 2 diabetes mellitus, in conjunction with diet and exercise. 

 

 

---

 

 

Contraindications

 

Patients should not use Mounjaro® if they:

 

• Are pregnant, possibly pregnant, or breastfeeding.

• Have type 1 diabetes mellitus, diabetic ketoacidosis, or are in a diabetic coma.

• Have a history of pancreatitis.

• Suffer from severe gastrointestinal disorders like gastroparesis.

• Have severe infections or are undergoing surgery.

• Are unable to maintain adequate nutrition or are in a debilitated state.

• Engage in strenuous physical activity or consume large amounts of alcohol.

• Have proliferative diabetic retinopathy or diabetic macular edema requiring acute treatment.